110 related articles for article (PubMed ID: 18582817)
1. Drotrecogin alpha (activated) in septic shock after lung transplant.
Feltracco P; Rea F; Ori C
J Heart Lung Transplant; 2008 Jul; 27(7):815. PubMed ID: 18582817
[No Abstract] [Full Text] [Related]
2. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.
Crum NF; Groff HL; Parrish JS; Ring W
Clin Infect Dis; 2004 Dec; 39(11):e122-3. PubMed ID: 15578351
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alpha (activated) in neonatal septic shock.
Frommhold D; Birle A; Linderkamp O; Zilow E; Pöschl J
Scand J Infect Dis; 2005; 37(4):306-8. PubMed ID: 15804668
[TBL] [Abstract][Full Text] [Related]
4. Use of activated protein C in a case of paediatric septic shock.
Verre M; Barozzi E; Piccirillo M; Tancioni F; Tiburzi S; Varano M
Minerva Pediatr; 2005 Dec; 57(6):429-32. PubMed ID: 16402015
[TBL] [Abstract][Full Text] [Related]
5. The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: case series and review of the literature.
Funk DJ; Palma Vargas J; Tuttle-Newhall J; Moretti EW
Transpl Infect Dis; 2011 Dec; 13(6):592-7. PubMed ID: 21794040
[TBL] [Abstract][Full Text] [Related]
6. [On activated protein C in septic shock].
Offenstadt G
Presse Med; 2006 Jun; 35(6 Pt 1):989; author reply 989. PubMed ID: 16783262
[No Abstract] [Full Text] [Related]
7. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.
Bachli EB; Vavricka SR; Walter RB; Leschinger MI; Maggiorini M
Intensive Care Med; 2003 Feb; 29(2):337. PubMed ID: 12594601
[No Abstract] [Full Text] [Related]
8. Activated protein C and septic shock: a propensity-matched cohort study*.
Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
[TBL] [Abstract][Full Text] [Related]
9. Drotrecogin alfa (activated) in septic shock.
Nayyar V; Solano T
N Engl J Med; 2012 Sep; 367(10):968-9; author reply 969. PubMed ID: 22931268
[No Abstract] [Full Text] [Related]
10. Drotrecogin alfa (activated) in septic shock.
Hollander JE
N Engl J Med; 2012 Sep; 367(10):968; author reply 969. PubMed ID: 22931267
[No Abstract] [Full Text] [Related]
11. "All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.
Barie PS
Surg Infect (Larchmt); 2007 Oct; 8(5):491-4. PubMed ID: 17999581
[No Abstract] [Full Text] [Related]
12. Treatment of Strongyloides stercoralis hyperinfection-associated septic shock and acute respiratory distress syndrome with drotrecogin alfa (activated) in a renal transplant recipient.
Huston JM; Eachempati SR; Rodney JR; Cayci C; Fusco D; Mathew M; Shou J; Goldstein MJ; Kapur S; Barie PS
Transpl Infect Dis; 2009 Jun; 11(3):277-80. PubMed ID: 19392733
[TBL] [Abstract][Full Text] [Related]
13. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
[TBL] [Abstract][Full Text] [Related]
14. [Activated protein C in patients with septic shock: pro].
Marx G
Dtsch Med Wochenschr; 2010 Nov; 135(47):2370. PubMed ID: 21082530
[No Abstract] [Full Text] [Related]
15. [Activated protein C in patients with septic shock: contra].
Graf J
Dtsch Med Wochenschr; 2010 Nov; 135(47):2371. PubMed ID: 21082531
[No Abstract] [Full Text] [Related]
16. Septic shock--evaluating another failed treatment.
Wenzel RP; Edmond MB
N Engl J Med; 2012 May; 366(22):2122-4. PubMed ID: 22616829
[No Abstract] [Full Text] [Related]
17. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.
Bilbault P; Lavaux T; Launoy A; Gaub MP; Meyer N; Oudet P; Pottecher T; Jaeger A; Schneider F
Crit Care Med; 2007 Jan; 35(1):69-75. PubMed ID: 17133181
[TBL] [Abstract][Full Text] [Related]
18. Drotrecogin alfa (activated) for nonmenstrual toxic shock syndrome associated with methicillin resistant Staphylococcus aureus infection.
Haddadin DW; Samnani IQ; Moorman JP
South Med J; 2006 Nov; 99(11):1295-6. PubMed ID: 17195430
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?
Opal SM; LaRosa SP
Am J Respir Crit Care Med; 2013 May; 187(10):1041-3. PubMed ID: 23675711
[No Abstract] [Full Text] [Related]
20. Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alpha (activated).
Al-Sabah S; Goldberg P; Qureshi ST
Transpl Infect Dis; 2007 Sep; 9(3):233-6. PubMed ID: 17692071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
